Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3′ Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-05-07

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-2828PMID 20453058
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?

  2010cited by this paper
• Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways

  2010cited by this paper
• Inhibition of PI3K and MEK: It Is All about Combinations and Biomarkers

  2009cited by this paper
• Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

  2009cited by this paper
• V600EBRAF is associated with disabled feedback inhibition of RAF–MEK signaling and elevated transcriptional output of the pathway

  2009cited by this paper
• AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.

  2009cited by this paper
• Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.

  2009cited by this paper
• A complex interplay between Akt, TSC2 and the two mTOR complexes.

  2009cited by this paper
• Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.

  2009cited by this paper
• In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

  2009influential reference
• Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

  2009cited by this paper
• Modulation of HER3 Is a Marker of Dynamic Cell Signaling in Ovarian Cancer: Implications for Pertuzumab Sensitivity

  2009cited by this paper
• Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes

  2009cited by this paper
• NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

  2008cited by this paper
• HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer

  2008cited by this paper
• The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer .

  2008cited by this paper
• Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer.

  2008cited by this paper
• Insights into the oncogenic effects of /PIK3CA/ mutations from the structure of p110α/p85α

  2008cited by this paper
• Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair

  2008cited by this paper
• PI3K pathway alterations in cancer: variations on a theme

  2008cited by this paper
• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  2008influential reference
• Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

  2008cited by this paper
• Breast Tumor Cells with PI3K Mutation or HER2 Amplification Are Selectively Addicted to Akt Signaling

  2008cited by this paper
• Predicting features of breast cancer with gene expression patterns

  2008cited by this paper
• Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer.

  2008cited by this paper
• Mechanism of Two Classes of Cancer Mutations in the Phosphoinositide 3-Kinase Catalytic Subunit

  2007cited by this paper
• A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

  2007influential reference
• Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

  2007cited by this paper
• A Modular Analysis of Breast Cancer Reveals a Novel Low-Grade Molecular Signature in Estrogen Receptor–Positive Tumors

  2006cited by this paper
• Turnover of the Active Fraction of IRS1 Involves Raptor-mTOR- and S6K1-Dependent Serine Phosphorylation in Cell Culture Models of Tuberous Sclerosis

  2006influential reference
• Genomic and transcriptional aberrations linked to breast cancer pathophysiologies.

  2006cited by this paper
• mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

  2006cited by this paper
• A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.

  2006cited by this paper
• Drugging the PI3 kinome

  2006cited by this paper
• Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.

  2006cited by this paper
• Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer.

  2006cited by this paper
• Role of HER2/HER3 co-receptor in breast carcinogenesis.

  2005cited by this paper
• On identification

  2005cited by this paper
• An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival.

  2005cited by this paper
• Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic.

  2005cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Statistical significance for genomewide studies

  2003cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

  2002cited by this paper
• p27Kip1 is required for PTEN-induced G1 growth arrest.

  2001cited by this paper
• A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes

  2001cited by this paper
• PIK3CA is implicated as an oncogene in ovarian cancer

  1999cited by this paper
• Cluster analysis and display of genome-wide expression patterns.

  1998cited by this paper
• TreeView: an application to display phylogenetic trees on personal computers

  1996cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper

• Distinct mRNA expression profiles and miRNA regulators of the PI3K/AKT/mTOR pathway in breast cancer: insights into tumor progression and therapeutic targets

  2025cites this paper
• Blockade of the PGE2 pathway inhibits the growth of PTEN deficient HNSCC tumors.

  2025cites this paper
• Phase II Study of Copanlisib in Patients With PTEN Loss: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols Z1G and Z1H

  2025cites this paper
• Establishment and characterization of preclinical model of primary ovarian squamous cell carcinoma

  2025cites this paper
• Mutation of PTEN: Loss and Likelihood of Being a Non-responder to Trastuzumab in a Sample of Iraqi Her2+ Breast Cancer Patients

  2024cites this paper
• Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D

  2024cites this paper
• Predictive, preventive, and personalized medicine in breast cancer: targeting the PI3K pathway

  2024cites this paper
• Unveiling the Role of PIK3R1 in Cancer: A Comprehensive Review of Regulatory Signaling and Therapeutic Implications.

  2024cites this paper
• Navigating the Complexity of PI3K/AKT Pathway in HER-2 Negative Breast Cancer: Biomarkers and Beyond.

  2024cites this paper
• Chronic exposure to low levels of parabens increases mammary cancer growth and metastasis in mice.

  2023cites this paper
• Discovery of novel potent PI3K/mTOR dual‐target inhibitors based on scaffold hopping: Design, synthesis, and antiproliferative activity

  2023cites this paper
• Current State and Future Challenges for PI3K Inhibitors in Cancer Therapy

  2023cites this paper
• Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK)

  2023cites this paper
• Differential Susceptibility of Ex Vivo Primary Glioblastoma Tumors to Oncolytic Effect of Modified Zika Virus

  2023cites this paper
• A Novel Dual PI3K/mTOR Inhibitor, XIN-10, for the Treatment of Cancer

  2023cites this paper
• Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

  2022cites this paper
• The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer—A Preliminary Study

  2021cites this paper
• Inhibition of Phosphatidylinositol 3-Kinase by Pictilisib Blocks Influenza Virus Propagation in Cells and in Lungs of Infected Mice

  2021cites this paper
• High MMP-11 expression associated with low CD8+ T cells decreases the survival rate in patients with breast cancer

  2021cites this paper
• Research update on the anticancer effects of buparlisib.

  2021cites this paper
• Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer

  2021cites this paper
• Feedback activation of STAT3 limits the response to PI3K/AKT/mTOR inhibitors in PTEN-deficient cancer cells

  2021cites this paper
• Inhibitors of cyclin-dependent kinases 4/6 for breast cancer patients with different somatic mutations of the PIK3CA gene

  2020cites this paper
• PI3K inhibition as a novel therapeutic strategy for neoadjuvant chemoradiotherapy resistant oesophageal adenocarcinoma

  2020cites this paper
• Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer

  2020cites this paper
• Phase 2 Study of TAS-117 in Advanced Solid Tumors Harboring Phosphatidylinositol 3-Kinase/v-akt Murine Thymoma Viral Oncogene Homolog Gene Aberrations

  2020cites this paper
• The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis

  2020cites this paper
• Case Report: Sustained Complete Response to PI3K Inhibition in a Patient with Metastatic Breast Cancer Harboring PIK3CA, NF1, and CDH1 Mutations.

  2020cites this paper
• Indazole scaffold: a generalist for marketed and clinical drugs

  2020cites this paper
• p110δ PI3K as a therapeutic target of solid tumours.

  2020cites this paper
• Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations

  2020cites this paper
• Indazole as a Privileged Scaffold: The Derivatives and their Therapeutic Applications.

  2020cites this paper
• Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

  2019cites this paper
• Targeting PI3K in cancer: mechanisms and advances in clinical trials

  2019cites this paper
• C-LabeledPictilisib (GDC-0941) as aMolecularTracerTargeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging

  2019cites this paper
• Chapter 2 Profiling mTOR Pathway in Neuroendocrine Tumors

  2019cites this paper
• 11C-Labeled Pictilisib (GDC-0941) as a Molecular Tracer Targeting Phosphatidylinositol 3-Kinase (PI3K) for Breast Cancer Imaging

  2019cites this paper
• PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases

  2019cites this paper
• Structural prediction, whole exome sequencing and molecular dynamics simulation confirms p.G118D somatic mutation of PIK3CA as functionally important in breast cancer patients

  2019cites this paper
• Dual PI3K/mTOR Inhibitor, XL765, suppresses glioblastoma growth by inducing ER stress-dependent apoptosis

  2019cites this paper
• HER2-L755S mutation induces hyperactive MAPK and PI3K-mTOR signaling, leading to resistance to HER2 tyrosine kinase inhibitor treatment

  2019cites this paper
• Tubulin mRNA stability is sensitive to change in microtubule dynamics caused by multiple physiological and toxic cues

  2019cites this paper
• High-Complexity shRNA Libraries and PI3 Kinase Inhibition in Cancer: High-Fidelity Synthetic Lethality Predictions.

  2019cites this paper
• Eukaryotic initiation factor 4E-binding protein as an oncogene in breast cancer

  2019cites this paper
• Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models

  2019cites this paper
• Design, synthesis and biological evaluation of substituted 2-(thiophen-2-yl)-1,3,5-triazine derivatives as potential dual PI3Kα/mTOR inhibitors.

  2019cites this paper
• Breast

  2019cites this paper
• Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study

  2019cites this paper
• PIK3CA mutation sensitizes breast cancer cells to synergistic therapy of PI3K inhibition and AMPK activation

  2018cites this paper
• The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts.

  2018cites this paper
• A novel PI3K/mTOR dual inhibitor XH002 exhibited robust antitumor activity in NSCLC

  2018cites this paper
• Genomic Applications in Pulmonary Malignancies

  2018cites this paper
• Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages

  2018cites this paper
• Blocked recombinase polymerase amplification for mutation analysis of PIK3CA gene.

  2018cites this paper
• KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

  2018cites this paper
• A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer

  2018cites this paper
• Discovery of an Orally Bioavailable Dual PI3K/mTOR Inhibitor Based on Sulfonyl-Substituted Morpholinopyrimidines.

  2018cites this paper
• Diet boosts the effectiveness of a cancer drug

  2018cites this paper
• Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

  2018cites this paper
• Protective effects of PI3KCG gene on acute myocardial infarction.

  2018cites this paper
• Computational Design of Multi-Target Drugs Against Breast Cancer

  2018cites this paper
• Targeting the CDK4/6-Rb Pathway Enhances Response to PI3K Inhibition in PIK3CA-Mutant Lung Squamous Cell Carcinoma

  2018cites this paper
• Efficacy of buparlisib in treating breast cancer

  2017cites this paper
• The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer

  2017influential citation
• Inhibitors of STAT3, β‐catenin, and IGF‐1R sensitize mouse PIK3CA‐mutant breast cancer to PI3K inhibitors

  2017cites this paper
• Autophagy promotes escape from phosphatidylinositol 3‐kinase inhibition in estrogen receptor‐positive breast cancer

  2017cites this paper
• A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.

  2017cites this paper
• Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

  2017cites this paper
• Discovery of New Aminosubstituted Pyrrolopyrimidines with Antiproliferative Activity Against Breast Cancer Cells and Investigation of their Effect Towards the PI3Kα Enzyme.

  2017cites this paper
• No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis

  2017cites this paper
• A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors.

  2017cites this paper
• Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer

  2017cites this paper
• Investigation of the role of alpha-casein and downstream signalling in breast cancer initiation and progression

  2017cites this paper
• Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

  2017cites this paper
• No Significant Association between PIK 3 CA Mutation and Survival of Esophageal Squamous Cell Carcinoma : A Meta-analysis

  2017cites this paper
• PI3K Inhibitors Synergize with FGFR Inhibitors to Enhance Antitumor Responses in FGFR2mutant Endometrial Cancers

  2017cites this paper
• The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era

  2017cites this paper
• Mass spectrometry imaging of lipid profiles in disease

  2017cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.

  2016cites this paper
• mTOR Inhibition Beyond Rapalogs

  2016cites this paper
• Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy

  2016cites this paper
• Downregulation of AKT3 Increases Migration and Metastasis in Triple Negative Breast Cancer Cells by Upregulating S100A4

  2016cites this paper
• Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics

  2016cites this paper
• Computational Framework for the Dissection of Cancer Genomic Architecture and its Association in Different Biomarkers

  2016cites this paper
• HER2 Signaling Network in Advanced Breast Cancer: Opportunities for Combination Therapies

  2016cites this paper
• Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, placebo-controlled, phase II randomised PEGGY study.

  2016cites this paper
• Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition

  2016cites this paper
• Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha–Positive, PIK3CA-Mutant Breast Cancer

  2016cites this paper
• Development and Application of a Microfluidics-Based Panel in the Basal/Luminal Transcriptional Characterization of Archival Bladder Cancers

  2016cites this paper
• Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

  2016cites this paper
• In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC

  2016cites this paper
• Design strategies, structure activity relationship and mechanistic insights for purines as kinase inhibitors.

  2016cites this paper
• Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer

  2016cites this paper
• Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers.

  2016cites this paper
• Subcellular localization of FOXO3a as a potential biomarker of response to combined treatment with inhibitors of PI3K and autophagy in PIK3CA-mutant cancer cells

  2016cites this paper
• PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment

  2016cites this paper
• Targeting the PI3K/Akt pathway in murine MDS/MPN driven by hyperactive Ras

  2016cites this paper
• Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

  2016cites this paper
• PIK3CA dependence and sensitivity to therapeutic targeting in urothelial carcinoma

  2016cites this paper